PharmaCyte Biotech, Inc.
PMCB · NASDAQ
4/30/2025 | 4/30/2024 | 4/30/2023 | 4/30/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $15 | $50 | $68 | $85 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $4 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $3 | $0 | $0 | $0 |
| Total Curr. Assets | $22 | $50 | $68 | $85 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $2 | $2 | $4 | $4 |
| Long-Term Investments | $22 | $8 | $2 | $2 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $9 | $0 | $0 | $0 |
| Total NC Assets | $33 | $9 | $5 | $5 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $55 | $60 | $73 | $91 |
| Liabilities | – | – | – | – |
| Payables | $0 | $0 | $0 | $0 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $3 | $7 | $0 | $0 |
| Total Curr. Liab. | $3 | $7 | $1 | $1 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $13 | $0 | $0 |
| Total NC Liab. | $0 | $13 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | -$0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $3 | $20 | $1 | $1 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $12 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$85 | -$116 | -$116 | -$112 |
| AOCI | -$0 | -$0 | -$0 | -$0 |
| Other Equity | $137 | $143 | $189 | $202 |
| Total Equity | $52 | $40 | $73 | $90 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $55 | $60 | $73 | $91 |
| Net Debt | -$15 | -$50 | -$68 | -$85 |